Tetralogic Pharmaceuticals Corp Stock Probability of Future Pink Sheet Price Finishing Over 1.0E-4
| TLOG Stock | USD 0.0001 0.00 0.00% |
TetraLogic |
TetraLogic Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of TetraLogic Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for TetraLogic Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| TetraLogic Pharmaceuticals generated a negative expected return over the last 90 days | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
TetraLogic Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TetraLogic Pink Sheet often depends not only on the future outlook of the current and potential TetraLogic Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. TetraLogic Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.7 M | |
| Cash And Short Term Investments | 20.4 M |
TetraLogic Pharmaceuticals Technical Analysis
TetraLogic Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. TetraLogic Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of TetraLogic Pharmaceuticals Corp. In general, you should focus on analyzing TetraLogic Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
TetraLogic Pharmaceuticals Predictive Forecast Models
TetraLogic Pharmaceuticals' time-series forecasting models is one of many TetraLogic Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary TetraLogic Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about TetraLogic Pharmaceuticals
Checking the ongoing alerts about TetraLogic Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for TetraLogic Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| TetraLogic Pharmaceuticals generated a negative expected return over the last 90 days | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Other Information on Investing in TetraLogic Pink Sheet
TetraLogic Pharmaceuticals financial ratios help investors to determine whether TetraLogic Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TetraLogic with respect to the benefits of owning TetraLogic Pharmaceuticals security.